230 related articles for article (PubMed ID: 29058481)
1. Effects of antiretroviral treatment and nadir CD4 count in progression to cardiovascular events and related comorbidities in a HIV Brazilian cohort: a multi-stage approach.
Oliveira RVC; Shimakura SE; Campos DP; Hökerberg YHM; Victoriano FP; Ribeiro S; Veloso VG; Grinsztejn B; Carvalho MS
AIDS Care; 2018 May; 30(5):551-559. PubMed ID: 29058481
[TBL] [Abstract][Full Text] [Related]
2. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
3. Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States.
Melekhin VV; Shepherd BE; Jenkins CA; Stinnette SE; Rebeiro PF; Bebawy SS; Rasbach DA; Hulgan T; Sterling TR
AIDS Patient Care STDS; 2010 May; 24(5):279-86. PubMed ID: 20438375
[TBL] [Abstract][Full Text] [Related]
4. Comparison of clinical response to initial highly active antiretroviral therapy in the patients in clinical care in the United States and Brazil.
Grinsztejn B; Veloso VG; Pilotto JH; Campos DP; Keruly JC; Moore RD
J Acquir Immune Defic Syndr; 2007 Aug; 45(5):515-20. PubMed ID: 17558332
[TBL] [Abstract][Full Text] [Related]
5. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).
Jaén A; Esteve A; Miró JM; Tural C; Montoliu A; Ferrer E; Riera M; Segura F; Force L; Sued O; Vilaró J; Garcia I; Masabeu A; Altès J; Coltet B; Podzamczer D; Murillas J; Navarro G; Gatell JM; Casabona J;
J Acquir Immune Defic Syndr; 2008 Feb; 47(2):212-20. PubMed ID: 18297762
[TBL] [Abstract][Full Text] [Related]
6. Aging with HIV: an overview of an urban cohort in Rio de Janeiro (Brazil) across decades of life.
Torres TS; Cardoso SW; Velasque Lde S; Marins LM; Oliveira MS; Veloso VG; Grinsztejn B
Braz J Infect Dis; 2013; 17(3):324-31. PubMed ID: 23602466
[TBL] [Abstract][Full Text] [Related]
7. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study.
Miller V; Mocroft A; Reiss P; Katlama C; Papadopoulos AI; Katzenstein T; van Lunzen J; Antunes F; Phillips AN; Lundgren JD
Ann Intern Med; 1999 Apr; 130(7):570-7. PubMed ID: 10189326
[TBL] [Abstract][Full Text] [Related]
8. Impact of Age-related Comorbidities on Five-year Overall Mortality among Elderly HIV-Infected Patients in the Late HAART Era--Role of Chronic Renal Disease.
Hentzien M; Dramé M; Allavena C; Jacomet C; Valantin MA; Cabié A; Cuzin L; Rey D; Pugliese P; Bani-Sadr F;
J Nutr Health Aging; 2016 Apr; 20(4):408-14. PubMed ID: 26999241
[TBL] [Abstract][Full Text] [Related]
9. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
10. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
Ho C; Lee S; Wong Kh; Cheng L; Lam M
HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
[TBL] [Abstract][Full Text] [Related]
11. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy.
Hulgan T; Shepherd BE; Raffanti SP; Fusco JS; Beckerman R; Barkanic G; Sterling TR
J Infect Dis; 2007 Feb; 195(3):425-31. PubMed ID: 17205482
[TBL] [Abstract][Full Text] [Related]
12. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
[TBL] [Abstract][Full Text] [Related]
13. Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution.
Arici C; Ripamonti D; Ravasio V; Maggiolo F; Rizzi M; Finazzi MG; Suter F
Int J STD AIDS; 2001 Sep; 12(9):573-81. PubMed ID: 11516366
[TBL] [Abstract][Full Text] [Related]
14. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.
Kohli R; Lo Y; Howard AA; Buono D; Floris-Moore M; Klein RS; Schoenbaum EE
Clin Infect Dis; 2005 Sep; 41(6):864-72. PubMed ID: 16107987
[TBL] [Abstract][Full Text] [Related]
15. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
16. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
[TBL] [Abstract][Full Text] [Related]
17. [Cardiovascular risk factors associated with antiretroviral therapy].
Pérez-Camacho I; Camacho A; Torre-Cisneros J; Rivero A
Enferm Infecc Microbiol Clin; 2009 Sep; 27 Suppl 1():24-32. PubMed ID: 20172412
[TBL] [Abstract][Full Text] [Related]
18. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
Panel de expertos de GESIDA y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
[TBL] [Abstract][Full Text] [Related]
19. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.
Hammer SM; Eron JJ; Reiss P; Schooley RT; Thompson MA; Walmsley S; Cahn P; Fischl MA; Gatell JM; Hirsch MS; Jacobsen DM; Montaner JS; Richman DD; Yeni PG; Volberding PA;
JAMA; 2008 Aug; 300(5):555-70. PubMed ID: 18677028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
